{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:38:02Z","timestamp":1791437882772,"version":"4.3.3"},"reference-count":45,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["P30CA072720"],"award-info":[{"award-number":["P30CA072720"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Bladder cancer (BC) is one of the most common malignancies in the United States, with over 80,000 new cases and 16,000 deaths each year. Urothelial carcinoma (UC) is the most common histology and accounts for 90% of cases. BC management is complicated by recurrence rates of over 50% in both muscle-invasive and non-muscle-invasive bladder cancer. As such, the American Urological Association (AUA) recommends that patients undergo close surveillance during and after treatment. This surveillance is in the form of cystoscopy or imaging tests, which can be invasive and costly tests. Considering this, there have been recent pushes to find complements to bladder cancer surveillance. Cell-free DNA (CfDNA), or DNA released from dying cells, and circulating tumor DNA (ctDNA), or mutated DNA released from tumor cells, can be analyzed to detect and characterize the molecular characteristics of tumors. Research has shown promising results for ctDNA use in the BC care realm. A PubMed literature review was performed finding studies discussing cfDNA and ctDNA in BC detection, prognostication, and monitoring for recurrence. Keywords used included bladder cancer, cell-free DNA, circulating tumor DNA, urothelial carcinoma, and liquid biopsy. Studies show that ctDNA can serve as prognostic indicators of both early- and late-stage BC, aid in risk stratification prior to major surgery, assist in detection of disease progression and metastatic relapse, and can assess patients who may respond to immunotherapy. The benefit of ctDNA is not confined to BC, as studies have also suggested its promise as a biomarker for neoadjuvant chemotherapy in upper-tract UC. However, there are some limitations to ctDNA that require improvements in ctDNA-specific detection methods and BC-specific mutations before widespread utilization can be achieved. Further prospective, randomized trials are needed to elucidate the true potential ctDNA has in advancements in BC care.<\/jats:p>","DOI":"10.3390\/jcm13072057","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T10:58:31Z","timestamp":1712055511000},"page":"2057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma"],"prefix":"10.3390","volume":"13","author":[{"given":"Sophia","family":"Bhalla","sequence":"first","affiliation":[{"name":"Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson University Hospital, 195 Albany St., New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Passarelli","sequence":"additional","affiliation":[{"name":"Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson University Hospital, 195 Albany St., New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antara","family":"Biswas","sequence":"additional","affiliation":[{"name":"Center for Systems and Computational Biology, Rutgers Cancer Institute of New Jersey, Rutgers University, 195 Albany St., New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhajyoti","family":"De","sequence":"additional","affiliation":[{"name":"Center for Systems and Computational Biology, Rutgers Cancer Institute of New Jersey, Rutgers University, 195 Albany St., New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8901-0210","authenticated-orcid":false,"given":"Saum","family":"Ghodoussipour","sequence":"additional","affiliation":[{"name":"Division of Urology, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson University Hospital, 195 Albany St., New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2021, September 10). Key Statistics for Bladder Cancer. Updated 13 January 2023. Available online: https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., Padala, S.A., and Barsouk, A. (2020). Epidemiology of Bladder Cancer. Med. Sci., 8.","DOI":"10.3390\/medsci8010015"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ng.687","article-title":"A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci","volume":"42","author":"Rothman","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000052494","article-title":"Bladder cancer. I. Molecular and genetic basis of carcinogenesis","volume":"39","author":"Brandau","year":"2001","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.urolonc.2012.04.006","article-title":"The characteristics of bladder cancer after radiotherapy for prostate cancer","volume":"31","author":"Abern","year":"2013","journal-title":"Urol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11912-021-01091-1","article-title":"Approaches to Non-Muscle-Invasive Bladder Cancer","volume":"23","author":"Slovacek","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer\u2014A clinical perspective","volume":"19","author":"Teoh","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Carrasco, R., Ingelmo-Torres, M., G\u00f3mez, A., Trullas, R., Rold\u00e1n, F.L., Ajami, T., Moreno, D., Rodr\u00edguez-Carunchio, L., Alcaraz, A., and Izquierdo, L. (2022). Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911732"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.acuro.2019.08.009","article-title":"Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy. Efecto de la quimioterapia adyuvante en el carcinoma urotelial de vejiga localmente avanzado tratado con cistectom\u00eda","volume":"44","author":"Amo","year":"2020","journal-title":"Actas Urol. Esp. (Engl. Ed.)"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/BLC-150034","article-title":"Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)","volume":"2","author":"Power","year":"2016","journal-title":"Bladder Cancer."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: Costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: An updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.5489\/cuaj.1205","article-title":"Surveillance strategies after definitive therapy of invasive bladder cancer","volume":"3","author":"Cagiannos","year":"2009","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wong, V.K., Ganeshan, D., Jensen, C.T., and Devine, C.E. (2021). Imaging and Management of Bladder Cancer. Cancers, 13.","DOI":"10.3390\/cancers13061396"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4274\/Mirt.138","article-title":"Limits of Tumor Detectability in Nuclear Medicine and PET","volume":"21","author":"Erdi","year":"2012","journal-title":"Mol. Imaging Radionucl. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.21037\/tau.2019.11.31","article-title":"Perioperative immunotherapy for muscle-invasive bladder cancer","volume":"9","author":"Kim","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.soc.2019.08.003","article-title":"Genomics and the History of Precision Oncology","volume":"29","author":"Doroshow","year":"2020","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41551-021-00837-3","article-title":"Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics","volume":"6","author":"Song","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lin, C., Liu, X., Zheng, B., Ke, R., and Tzeng, C.M. (2021). Liquid Biopsy, ctDNA Diagnosis through NGS. Life, 11.","DOI":"10.3390\/life11090890"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103109","DOI":"10.1016\/j.critrevonc.2020.103109","article-title":"ctDNA as a cancer biomarker: A broad overview","volume":"155","author":"Pessoa","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer","volume":"70","author":"Nordentoft","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis","volume":"73","author":"Christensen","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma\u2014Upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14737140.2019.1626723","article-title":"Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: A meta-analysis","volume":"19","author":"Cao","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"657483","DOI":"10.3389\/fonc.2021.657483","article-title":"Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fonc.2020.00755","article-title":"Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer","volume":"10","author":"Hayashi","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.22.00763","article-title":"Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma","volume":"41","author":"Coleman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2023.09.017","article-title":"Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma","volume":"85","author":"Huelster","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.euo.2023.03.008","article-title":"Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314","volume":"6","author":"Lu","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14737140.2022.2038565","article-title":"Adjuvant immunotherapy for muscle-invasive urothelial carcinoma of the bladder","volume":"22","author":"Alevizakos","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: A study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Toms","year":"2023","journal-title":"Future Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-3-030-26439-0_10","article-title":"Enrichment and Analysis of ctDNA","volume":"215","author":"Gilson","year":"2020","journal-title":"Recent Results Cancer Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/7\/2057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:22:31Z","timestamp":1760106151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/7\/2057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["jcm13072057"],"URL":"https:\/\/doi.org\/10.3390\/jcm13072057","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]}}}